Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial-Reference-Cited by-同舟云学术

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Published:2017-11 Issue:10107 Volume:390 Page:2063-2072
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Gallant Joel,Lazzarin Adriano,Mills Anthony,Orkin Chloe,Podzamczer Daniel,Tebas Pablo,Girard Pierre-Marie,Brar Indira,Daar Eric S,Wohl David,Rockstroh Jürgen,Wei Xuelian,Custodio Joseph,White Kirsten,Martin Hal,Cheng Andrew,Quirk Erin

Publisher

Elsevier BV

Subject

General Medicine

Reference27 articles.

1. Antiretroviral Drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society–USA panel;Gunthard;JAMA,2016

2. Raltegravir (RAL) 1200 mg once daily (QD) is non-inferior to RAL 400 mg twice daily (BID), in combination with tenofovir/emtricitabine, in treatment-naïve HIV-1-infected subjects: week 48 results;Cahn,2016

3. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration;Lancet,2008

4. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study;Worm;J Infect Dis,2010

5. Effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV Cohort Study;Young;J Acquir Immune Defic Syndr,2015

Cited by 272 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beware of resistance to 2nd-generation integrase inhibitors: A systematic meta-analysis of HIV-1 integrase inhibitors resistance and drug resistance mutations;International Journal of Antimicrobial Agents;2024-09

2. Switching Human Immunodeficiency Virus Therapy;Infectious Disease Clinics of North America;2024-09

3. Metabolic Complications Associated with Use of Integrase Strand Transfer Inhibitors (InSTI) for the Treatment of HIV-1 Infection: Focus on Weight Changes, Lipids, Glucose and Bone Metabolism;Current HIV/AIDS Reports;2024-08-29

4. Comparative evaluation of adverse drug reactions for tenofovir alafenamide and tenofovir disoproxil fumarate using the FAERS Database: a disproportionality analysis;Expert Opinion on Drug Safety;2024-08-19

5. Challenges for Novel Antiretroviral Development in an Era of Widespread tenofovir-disoproxil/lamivudine (or emtricitabine)/dolutegravir availability (TLD) Availability;Clinical Infectious Diseases;2024-07-11